MINDCURE signs exclusive digital clinical data license agreement with ATMA Journey Centers

Pay attention to use the patient data provided by ATMA to optimize iSTRYM, its digital therapeutic platform

VANCOUVER, BC, September 23, 2021 / PRNewswire / – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research on psychedelics, today announced a data licensing agreement with ATMA Journey Centers Inc. (“ATMA”), a pioneer in the psychedelic therapy industry and the first commercial company in Canada to legally treat a palliative patient with psychedelic therapy using psilocybin. This agreement is an extension of an existing partnership, whereby ATMA will grant MINDCURE an exclusive license to ATMA data from patients using the iSTRYM digital therapy software, with the aim of further optimizing the platform.

MINDCURE positions iSTRYM as the industry distribution network for scientific and evidence-based protocols and AI (artificial intelligence) data systems. iSTRYM is a unique software application that optimizes the healing journey for patients and clinicians before, during and after therapy sessions. iSTRYM was designed to change the paradigm of care and access to psychedelic-assisted psychotherapy, reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols . As a drug independent platform, iSTRYM was designed to support not only any type of psychedelic molecule in a treatment protocol, but also to support protocols that use existing drugs on the market or protocols therapies that might not need medication at all, as in traditional discourse. therapy.

MINDCURE initially plans to serve psychedelic clinics and expand into integrated clinics, both traditional and psychedelic, and eventually into the broader mental health market. In August, the company launched the minimum viable product (MVP) version of iSTRYM in partner clinics across North America. MINDCURE plans to begin full commercial deployment in the first quarter of 2022.

“We are delighted to extend our collaboration with the ATMA team. As data is a critical part of refining iSTRYM, access to ATMA’s network of therapists and anonymized patient data will improve our ability to deliver tools, protocols and treatments to therapists. , and enable us to tackle a global mental health crisis that needs a solution, ”said Kelsey ramsden, President and CEO of MINDCURE. “ATMA’s growing clinical footprint in Canada with its recently inaugurated center in Costa Rica gives MINDCURE the opportunity to deploy iSTRYM, with the aim of optimizing treatments for its patients and exposing iSTRYM to the data necessary to make the platform a trusted platform for therapists and patients worldwide whole.”

“Our partnership with ATMA is an exciting opportunity for MINDCURE to demonstrate the effectiveness of iSTRYM’s treatment protocols and to identify treatment components that are associated with optimal results for clients. It is at the heart of what we built iSTRYM for ” noted Ty tashiro, MINDCURE Senior Translational & Psychometric Architect. “This special collaboration will allow us to deploy iSTRYM’s multi-faceted assessment capabilities, including biometrics, natural language processing and unique psychometrics, to create a responsive and personalized treatment experience.

“We look forward to helping MINDCURE develop iSTRYM into the leading digital therapy platform for therapists conducting psychedelic-assisted psychotherapy. ” said David Harder, co-CEO and co-founder of ATMA. “Real patient data will further strengthen and improve the protocols we use and the effectiveness of the treatments we deliver at our Journey Centers.”

In related news, MINDCURE successfully launched iSTRYM’s Minimum Viable Product (MVP) on August 26, 2021. The company is on track to expand into more than ten clinics across Canada and the United States as part of the MVP beta testing program in Q4 2021.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovation and commercialization of new ways to promote healing and improve mental health. The Company is developing digital therapy technology and researching psychedelic compounds to promote access to safe and evidence-based psychedelic-assisted therapies around the world. Learn more at mindcure.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

About ATMA Journey Centers Inc.
ATMA is a private healthcare company with a mission to provide effective and innovative healing and transformative experiences that awaken the inner healer and foster a deeper connection with oneself, with others and with the beauty of the world. . A pioneer in the psychedelic therapy industry, ATMA is building a global network of psychedelic therapy clinics. ATMA was the first private sector service provider in Canada to announce the conduct of psychedelic-assisted forensic therapy for a palliative care patient under Health Canada’s Section 56 (1) exemption approval. . His team collectively has over 100 years of experience in the disciplines of medical work, integration, therapy and personal development.

On behalf of the board of directors
Kelsey ramsden, President and CEO
Phone: 1-888-593-8995

Forward-looking information
Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE management, including, but not limited to: the impact of the COVID-19 pandemic on the Canadian economy and MINDCURE activities, as well as the extent and duration of this impact; no changes in laws or regulations that adversely affect MINDCURE’s activities; there will be a demand for MINDCURE products in the future; no unforeseen expenses or costs arise; MINDCURE can continue to identify products that make them ideal candidates for providing mental health treatment solutions; that iSTRYM will be developed, optimized and function as intended in the psychedelics industry; that the Company will be effective in obtaining patents filed for the synthesis of ibogaine, or the synthesis of ibogaine, or the development of ibogaine synthesized for research, medical or commercial use; that MINDCURE will advance well-being around the world; that iSTRYM will undergo commercial deployment in the short term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur in the near future. ‘scale or within the timeframe envisaged; or that ATMA’s anonymized patient data will further optimize the iSTRYM platform or improve MINDCURE’s ability to deliver tools, protocols and treatments to therapists.

Although MINDCURE has attempted to identify significant factors that could cause actual results, performance or achievements to differ materially from those described in the forward-looking information presented, there may be other factors that cause actual results to differ. , performance or achievements differ from those anticipated, estimated or intended. Therefore, readers should not place undue reliance on forward-looking statements, as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE assumes no obligation to publicly update or revise any forward-looking information, whatsoever. either as a result of new information, events, or other.

SOURCE Mind Cure Health Inc.

About Terry Gongora

Check Also

Catastrophic casualty care is more than clinical. Workers compensation must understand the value of compassion

Although catastrophic injuries represent a small percentage of all workers’ compensation claims, for these injured …

Leave a Reply

Your email address will not be published.